These data from CARDIO-TTRansform were presented at HFSA 2026, highlighting positive data from the trial despite its failure to improve cardiovascular mortality.
|Articles|October 11, 2021
Cardiology Case Report: Syncope and COVID-19
Author(s)Brady Pregerson, MD
Our latest case report from Brady Pregerson, MD, features a woman in her 40s sent from a monoclonal antibody clinic to the ER for a syncopal episode. Check out the EKG and try to determine the correct diagnosis!
Advertisement
History: A woman in her mid-40’s is sent from a nearby monoclonal antibody clinic to the ER for a syncopal episode. She denies any injury or prodromal chest pain, SOB, palpitations, or other complaints beyond the low-grade fever and cough she has been having for the past week.
Exam: Vital signs are normal though the pulse is in the high 90’s. Exam is otherwise non-focal.
An EKG is done:
What is the most likely cause of the EKG?
Newsletter
Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.
SubscribeAdvertisement
Related to this article
A propensity-matched TriNetX analysis presented at ACG 2026 found lower MACE and mortality with resmetirom vs semaglutide over 2 years in MASLD/MASH.
A recent retrospective analysis presented at HFSA 2026 has demonstrated the association between GLP-1 agonists, weight reduction, and PA pressures.
A new analysis of the SEQUOIA-HCM trial, presented at HFSA 2026, demonstrates aficamten’s association with improvements to an understudied aspect of the condition.
A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.
A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.
Advertisement
Advertisement